Clinical Trial

Disease Characteristics and Treatment Response in Plasma Cell Disorders Patients Based on Genetic Abnormalities From Fluorescence In Situ Hybridization and Next Generation Sequencing

Study acronym: genetics MM
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 26, 2024 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this observational study is to study the genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand. The main questions it aims to answer are: * genetic landscape in patients with Plasma Cell Disorders including MGUS, SMM, MM, and amyloidosis in Thailand who were performed FISH and/or NGS testing * genetic correlation and genetic dependency between FISH and NGS, stratified by high- and standard-risk groups based on FISH testing in Thai MM patients. * disease characteristics and response rates in MM patients with cytogenetic abnormalities detected by FISH and/or genetic mutations detected by NGS. * correlation between cytogenetic abnormalities identified by FISH and genetic mutations detected by NGS with progression-free survival in MM patients. The FISH and/or NGS testing results, disease characteristics, treatment, and treatment outcomes of patients with plasma cell disorders who underwent FISH and/or NGS testing before IRB approval will be collected through retrospective chart review. Subsequently, data will be gathered prospectively. Participants will provide approximately 12 mL of bone marrow fluid for FISH and NGS testing.
Trial Details
NCT Number NCT06330896
Lead Sponsor Siriraj Hospital
Conditions Plasma Cell Disorder
Enrollment 498 participants
Start Date 2024-04-01
Primary Completion 2025-09-30 (estimated)
Study Completion 2028-04-01 (estimated)
Updated on ClinicalTrials.gov 2024-03-26